Table 1.
Clinicopathological characteristics for 516 bladder cancer patients.
| Characteristics | |
|---|---|
| Age, median (IQR) | 66 (57–73) |
| Gender | |
| female | 80 (15.5%) |
| male | 436 (84.5%) |
| Smoking history | |
| no | 355 (68.8%) |
| yes | 161 (31.2%) |
| Alcohol-drinking history | |
| no | 449 (87.0%) |
| yes | 67 (13%) |
| Hypertension | |
| no | 367 (71.1%) |
| yes | 149 (28.9%) |
| Histology subtype | |
| transitional cell carcinoma | 488 (94.6%) |
| non-transitional cell carcinoma | 28 (5.4%) |
| Grade | |
| 2 | 126 (24.4%) |
| 3 | 385 (75.6%) |
| T-stage | |
| NMIBC | 162 (31.4%) |
| MIBC | 354 (68.6%) |
| N-stage | |
| negative | 81 (15.7%) |
| positive | 435 (84.3%) |
| M-stage | |
| negative | 511 (99.03%) |
| positive | 5 (0.97%) |
| Adjunctive chemotherapy | |
| yes | 91 (17.6%) |
| no | 425 (82.4%) |
| ASA grade | |
| 1&2 | 436 (84.5%) |
| 3&4 | 80 (15.5%) |
| Anemia | |
| present | 144 (27.9%) |
| absent | 342 (72.1%) |
| Hypoalbuminemia | |
| present | 43 (8.3%) |
| absent | 442 (85.7%) |
| PLR, median (IQR) | 133.8 (98.22–180.23) |
| HALP, median (IQR) | 41.2 (27.78–58.71) |
IQR, interquartile range; MIBC, muscle-invasive bladder cancer; NMIBC, non-muscle invasive bladder cancer; ASA, American Society of Anesthesiologists; PLR: platelet to lymphocyte ratio.